Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know

- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -

Edwards Lifesciences (EW) closed at $194.73 in the latest trading session, marking a -0.35% move from the prior day. This change lagged the S&P 500’s daily loss of 0.16%. Meanwhile, the Dow lost 0.12%, and the Nasdaq, a tech-heavy index, lost 0.33%.

Coming into today, shares of the medical device maker had gained 2.28% in the past month. In that same time, the Medical sector lost 8.16%, while the S&P 500 lost 10.5%.

Investors will be hoping for strength from EW as it approaches its next earnings release. The company is expected to report EPS of $1.47, up 11.36% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $1.11 billion, up

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.72 per share and revenue of $4.55 billion. These totals would mark changes of +2.69% and +4.68%, respectively, from last year.

Investors might also notice recent changes to analyst estimates for EW. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company’s business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 8.68% lower. EW currently has a Zacks Rank of #3 (Hold).

Looking at its valuation, EW is holding a Forward P/E ratio of 34.16. Its industry sports an average Forward P/E of 27.11, so we one might conclude that EW is trading at a premium comparatively.

We can also see that EW currently has a PEG ratio of 2.2. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company’s expected earnings growth rate. EW’s industry had an average PEG ratio of 2.31 as of yesterday’s close.

The Medical – Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 36, which puts it in the top 15% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

Home of Science
Follow me

- Advertisement -

Discover

Sponsor

Latest

What Can Amazon Prime Do For You?

What Can Amazon Prime Do For You?Amazon Prime is very popular, which is probably why it is used as a marketing strategy. Although...

Over 4 million Americans are now skipping their mortgage payments

Fewer Americans are calling their mortgage servicers to ask for relief from mortgage payments, but the housing industry isn’t out of the woods yet. More...

Is a Hat Or Tie Mandatory?

Although a business dress code might make you feel like a walking punchline, many people do follow it and others even use it as...

OPEC and allies to decide on historic oil production cut as coronavirus ravages demand

KEY POINTS An emergency video meeting between OPEC and non-OPEC partners, sometimes referred to as OPEC+, started shortly after 4:10 p.m. Vienna time. Energy ministers...

Opinion: Google gives Wall Street what it wants, and the stock shoots higher

Alphabet Inc. executives are prioritizing share repurchases instead of continuing to spend on new employees and business development during the COVID-19 pandemic, and Wall...
Home of Science
Follow me